A case of tumour necrosis factor‐α inhibitor‐ and rituximab‐induced plantar pustular psoriasis that completely resolved with tocilizumab | Zendy

Jayasekera P. | Zendy; Parslew R. | Zendy; AlSharqi A. | Zendy

Premium

A case of tumour necrosis factor‐α inhibitor‐ and rituximab‐induced plantar pustular psoriasis that completely resolved with tocilizumab

Author(s) -

Jayasekera P.,

Parslew R.,

AlSharqi A.

Publication year - 2014

Publication title -

british journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.304

H-Index - 179

eISSN - 1365-2133

pISSN - 0007-0963

DOI - 10.1111/bjd.13146

Subject(s) - medicine , rituximab , tocilizumab , rheumatoid arthritis , psoriasis , psoriatic arthritis , tumor necrosis factor alpha , monoclonal , methotrexate , dermatology , arthritis , monoclonal antibody , immunology , antibody

Summary Rituximab, a chimeric B ‐cell‐depleting monoclonal antibody, is a well‐established therapy for rheumatoid arthritis. It is emerging that classical psoriatic lesions and plantar pustular psoriasis ( PPP ) are cutaneous side‐effects of this drug. Antitumour necrosis factor (anti‐ TNF ) therapies have multiple documented side‐effects including PPP and psoriasis. We report a patient who has rheumatoid arthritis, who failed on anti‐ TNF therapies and then was commenced on rituximab. Subsequently she developed localized PPP . Due to deterioration of her joint disease she was switched to the interleukin‐6 blocker tocilizumab, and the PPP resolved.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research